J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Alphabet Shifts AI Strategy Toward Commercial Growth, Goldman Sachs Says 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Add as a preferred source on Google
NEW YORK, May 12, 2017 -- Edison Investment Research Inc. (“Edison”), an investment research and advisory company, wishes to comment on statements made by Akari Therapeutics ("Akari") in its press release dated April 27, 2017 and the SEC filing dated May 11, 2017.
Edison’s analysts follow a strict and extensive review process prior to the publication of any report, including the April 26, 2017 note on Akari (the "Note"). Edison’s analyst team carried out the Edison Process, including engaging the client, Akari, to review and provide feedback on the report and notify us if any inaccuracies or misrepresentations appeared in the final draft of the Note. Following a review of the report by Akari’s senior management, Edison was provided with specific written approval for the publication of the Note as published.
Following the publication of the Note on April 26, 2017, Akari management contacted Edison to notify that “certain errors” were found in the Note without providing Edison with further explanation regarding the alleged errors. Akari management subsequently requested Edison retract the Note and announced “material inaccuracies” were found in the Note.
Despite an in-depth investigation, Edison has yet to find any evidence of inaccuracies nor have details of any alleged inaccuracies been provided by Akari representatives, despite multiple requests from Edison and by Edison’s legal counsel, Barton LLP, to Edison's legal counsel. Edison believes the published Note consistently reflected the accuracy of the information contained in and written by Akari in Akari’s press release dated April 24, 2017.
About Edison
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and Asia Pacific. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Contacts Peter Molloy Chief Executive Officer, Edison [email protected] Neil Shah Director of Research, Edison [email protected]
